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etal modActivating mutations in the FGFR3 gene cause Achondroplasia
(ACH)1,2 and Thanatophoric Dysplasia (TD)3,4. Both syndromes pre-
sent with severely shortened limbs and other skeletal abnormal-
ities, but TD is usually fatal in the perinatal period3,4. While
activating mutations in ACH and TD lead to mutant forms of
FGFR3 that impair chondrocyte proliferation and cartilage develop-
ment5, loss of Fgfr3 in mice enhances endochondral bone growth6,
revealing that FGFR3 acts as a negative regulator of this process.
Unfortunately, most individuals with TD die shortly after birth
due to skeletal malformations that occur before the disease is diag-
nosed, preventing pharmacological intervention, and treatment for
ACH is currently limited to symptom management. However, C-
type natriuretic peptide (CNP) has recently been identiﬁed as po-
tential therapeutic agent for ACH. CNP rescued growth defects in
a mouse model of ACH7 and a Phase 2 clinical trial is currently eval-
uating the effect of CNP on ACH (BioMarin; BMN-111). Neverthe-
less, further studies into the underlying mechanisms and novel
therapeutic possibilities are highly warranted.
In a ground-breaking study, Yamashita and colleagues8 created
induced pluripotent stem (iPS) cells derived from the skin of ACH
and TD patients, as well as controls, and screened candidate drugs
for restorative effects during chondrogenic induction. The result:
Statins, drugs that are commonly prescribed to lower cholesterol,
signiﬁcantly improved chondrogenesis of mutant iPS cells. More-
over, statins also corrected skeletal development in a mouse model
of ACH. The authors conclude that these results are due to reduced
cholesterol levels. These ﬁndings are intriguing from a therapeutic
perspective, in particular for the treatment of ACH, and increase our
understanding of skeletal development. However, they are some-
what at odds with prior studies on cholesterol signaling and
FGFR3 function in chondrocytes, as well as statin use in patients
with osteoarthritis (OA).
Cholesterol signaling plays an important role during embryonic
development, including the development of the skeletal system.
Pharmacological inhibition of local cholesterol synthesis in the
developing growth plate reduces expression of Indian hedgehog
(Ihh), a critical regulator of cartilage development, decreases
expression of the hypertrophic transcript Col10a1, and results international. Published by Elsevier Lin rats9. Evidence from our group suggests that cytoskel-
ulation stimulates the retinoid-related receptor alpha
(RORa), a known receptor for cholesterol, to promote chondrocyte
hypertrophy10. Furthermore, statin administration retarded bone
growth in control mouse embryonic tibial explants10, similar to
the effects seen in9. Somewhat contradictory to these observations,
Yamashita and colleagues report that statin treatment, and there-
fore inhibition of cholesterol synthesis, increases bone growth by
reducing constitutively active FGFR3 protein levels via proteasomal
destruction8. Although statin treatment rescued dwarﬁsm in mice
bearing FGFR3 ACH mutations, drug administration did not affect
bone development in controls. These ﬁndings highlight a complex
interplay between cholesterol signaling and cartilage development,
and suggest that statins play a role in regulating aberrant protein
abundance, at least in the case of mutant FGFR3. Further studies
that examine Ihh, RORa activation, and other effectors of choles-
terol signaling in ACH and TD iPS cells may help to elucidate the
molecular cross talk occurring upon mutant FGFR3 activation in
chondrogenesis. Potential explanations for the apparent discrep-
ancy in results include dose-dependent effects of cholesterol or sta-
tins, and/or additional effects of statins discussed below.
Given that OA pathogenesis recapitulates aspects of cartilage
development, studies of chondrogenesis can inform approaches
for OA prevention and treatment11. In fact, the reciprocal may
also be true. The relationship between statin use and OA has
been an active area of investigation for the past decade. Statins
act by inhibiting HMG-CoA reductase, a primary, rate-limiting
enzyme involved in cholesterol synthesis. However, statins also in-
ﬂuence other pathways downstream of HMG-CoA reductase
(Fig. 1). Amongst these pathways, protein farnesylation and gera-
nylgeranylation (forms of prenylation) may be the most important
since they regulate the activity of many crucial signaling molecules,
including Ras and Rho GTPases. Interestingly, statins and inhibitors
of farnesyl and geranylgeranyl transferases have protective effects
in models of OA. Expression of the collagenases MMP1, MMP3,
and MMP13 is reduced in OA chondrocytes upon statin treatment
in vitro12e14, an effect that is mimicked by geranylgeranyl trans-
ferase inhibition14 and that can be reversed by mevalonate, farne-
sol, or geranylgeranyl pyrophosphate supplementation12e14.
Statin treatment has also been shown to positively regulate compo-
nents of the extracellular matrix in a rabbit model of OA15, as well
as in chondrocytes cultured from OA patients13,14. Thus, statins
have been shown to be cartilage-protective in several studies, but
at least some of these effects are likely mediated by pathways other
than those involving cholesterol synthesis. Studies by us and others
have also demonstrated multiple roles of Rho GTPases during carti-
lage development (reviewed in16), raising the possibility that thetd. All rights reserved.
Fig. 1. Statins inﬂuence multiple cellular pathways. Statins inhibit HMG-CoA Reduc-
tase and, consequently, cholesterol synthesis and protein prenylation. How statins in-
ﬂuence protein degradation via the proteasome is not completely understood. Blue
lines indicate activation, Red lines indicate inhibition, and dashed lines indicate
possible but unconﬁrmed interactions.
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cholesterol-independent activities. Furthermore, the effects of sta-
tins on articular chondrocytes may provide novel insight regarding
the role of cholesterol homeostasis and signaling during cartilage
development.
From a clinical perspective, numerous large-cohort longitudinal
OA studies have generated intriguing yet contradictory observa-
tions. Statin use has been found to increase the risk of OA17 or to
have no effect on OA symptoms18, whereas other studies reported
that statin use decreased the prevalence of certain forms of
OA19e21. These discrepancies have been attributed to differences
in population demographics and study methodology, suggesting
that further investigations are needed to fully evaluate the potential
beneﬁts of statin use in preventing or treating OA.
Earlier interest in pursuing statin treatment for OA was mostly
based on the hypothesis that the anti-inﬂammatory effects of sta-
tins may be effective in this situation. However, could there be a
connection between OA pathogenesis and FGFR3 signaling? Based
on in vitro data obtained from control- and OA patient-derived
articular chondrocytes22, one would actually expect decreased
FGFR3 signaling to exacerbate cartilage destruction and OA patho-
genesis. In fact, deletion of Fgfr3 in articular chondrocytes leads to
early cartilage degradation and OA-like changes23. Furthermore,
genetic deletion of Fgfr1 in mice confers resistance to OA with
concomitant up-regulation of Fgfr324, suggesting that FGFR3 is pro-
tective against OA. However, it is likely that statins have pleiotropic
effects, perhaps also acting to modulate the protein abundance of
other signaling factors, such as FGFR1. Additional transcriptional
and proteomic studies in iPS cells from ACH and TD patients, as
well as in chondrocytes from OA patients, will be required to
address the complete effects of statins on developing and mature
chondrocytes.
One particularly interesting aspect of Yamashita and colleague's
work is the creation of patient-derived iPS cells and their screening
of drugs during in vitro iPS cell chondrogenesis8. While this
approach has proven valuable for elucidating the cellular pathology
of a number of monogenic diseases (in Marfan syndrome, for
example25), it has not been widely employed to study polygenic
or genetically heterogeneous conditions. Generating iPS cells
from OA patients (and controls) and subsequent differentiation
into articular chondrocytes could help to determine whether chon-
drocytes fromOA patients share similar, identiﬁable andmodiﬁablephenotypes. However, serious limitations to this approach must be
considered (see below), including the fact that many non-genetic
causes contribute to OA risk ad pathology. Provided that chondro-
genesis of iPS cells derived from OA patients recapitulates some as-
pects of the disease, as did those from patients with genetic
diseases (ACH, TD, and Marfan8,25), OA iPS cells would provide a
resource for screening drugs and testing therapies in vitro. Com-
bined with whole-genome sequencing, genotypeephenotype cor-
relations could also be made, potentially paving the way for OA
therapeutics based on genetic predispositions. Preliminary studies
using iPS cells derived from synovial cells have been encour-
aging26,27, and it will be interesting to see whether those derived
from skin ﬁbroblasts will behave similarly. Given the difﬁculties
associated with surgically obtaining chondrocytes from patients
(and in particular from controls), generating iPS cells from skin ﬁ-
broblasts and coaxing them to become chondrocytes may offer a
novel alternative to study the cellular defects in OA.
Still, several important caveats must be considered when pro-
posing to study iPS cells fromOA patients. First, increasing evidence
demonstrates that OA is a disease of the whole joint, not only carti-
lage28. It might be helpful to differentiate additional populations of
patient-derived iPS cells towards alternative lineages, such as oste-
oblasts or synovial cells, to further characterize the various cellular
behaviors in relevant tissue types. A second caveat is the limited
applicability of in vitro models for OA research. It is unclear how
much iPS cell-induced chondrocytes would mimic articular carti-
lage, whose phenotype is fundamentally different from the growth
plate chondrocytes recapitulated by Yamashita and colleagues.
Furthermore, while osteoarthritic chondrocytes have endured de-
cades of mechanical strain and environmental inﬂuence, chondro-
cytes derived from iPS cells will be naïve in this sense, and may not
accurately reﬂect the disease phenotype at the cellular level.
Finally, unlike ACH and TD, OA is not a purely genetic disease, as
physical or physiological insults are thought to initiate and drive
the progression of the disease in many cases28. Moreover, GWAS
studies of OA patients have yieldedmany genetic variants, but these
common polymorphisms seem to have mild to modest individual
effects29. It is therefore apparent that multiple genetic polymor-
phisms underlie the hereditary components in OA and that studies
of genetically heterogeneous iPS cells differentiated to chondro-
cytes may not facilitate testable hypotheses or widely applicable
results.
In conclusion, the discovery that statins can improve chondro-
genesis in ACH and TD iPS cells, as well as in an in vivomousemodel
of ACH, holds great promise for treating ACH. Additionally, the suc-
cessful use of patient-derived iPS cells differentiated to chondro-
cytes to screen therapeutic compounds highlights the potential of
this approach to develop treatments for monogenic disorders.
Similar approaches may be useful in identifying disease-relevant
pathways in OA but will be hampered by the heterogeneous and
multigenic nature of this complex disease that affects multiple tis-
sues in the joint. While the ﬁndings by Yamashita and colleagues
point to a potentially life-changing therapy for individuals coping
with ACH, they further obfuscate the relationship between statins,
FGFR3, and cartilage homeostasis. Additional studies are required
to elucidate the full suite of mechanisms by which statins correct
chondrogenesis in ACH and TD iPS cells, and to understand how
statin use and cholesterol homeostasis may differentially inﬂuence
chondrocytes in developmental stage-, context-, or genotype-
speciﬁc manners.
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